The role of Axl in melanoma metastasis by Kang, Jing
   
The role of Axl in melanoma metastasis 
By 
Jing Kang 
 
 
 
 
 
 
This thesis is submitted in partial fulfillment of the 
requirements for the degree of Master of Science 
 
University of Bergen 
The Department of Biomedicine 
Bergen, Norway 
June 2015 
 
 
  
Acknowledgements 
 
The work present in this thesis was carried out as part of the Master of Science degree in 
Medical Cell Biology at the Department of Biomedicine, University of Bergen, in the period 
August 2013 to June 2015. The laborious work was carried out at CELLNET group. 
First of all I would like to thank my main supervisor James B. Lorens for excellent scientific 
guidance and support throughout this period. I am so grateful for everything I have learned 
and for the opportunity to be a part of your fantastic lab. I also wish to thank my co-supervisor 
Niels Aarsæther for always being helpful and supportive, both in the lab and in the writing 
process. I have greatly appreciated all the advices and encouragement. I am also grateful for 
getting the opportunity to do my thesis on such an interesting and up to date field, with highly 
competent people.  
I will thank Kjersti Davidsen, Gry Sandvik Haaland, David Micklem, Magnus Blø and Sissel 
Vik Berge for their supports and guidance in the lab and for always being beyond positive, 
enthusiastic and helpful. I also like to thank Maren Stallemo and Stian Krog for their help, 
patience and support. I also express my gratitude to all people who have helped and 
encouraged me during my master study. 
Finally I will thank my wonderful family for always providing love, care and support. 
 
 
 
 
 
 
 
 
 
Bergen 2015 
Jing Kang  
Contents 
Abbreviations .......................................................................................................................................... 1 
Abstract ................................................................................................................................................... 2 
Introduction ............................................................................................................................................. 4 
1.1 Melanoma ...................................................................................................................................... 4 
1.1.1 Melanoma ............................................................................................................................... 4 
1.1.2 Metastatic melanoma .............................................................................................................. 4 
1.1.3 The treatment of melanoma .................................................................................................... 5 
1.2 Axl ................................................................................................................................................. 5 
1.2.1 Axl .......................................................................................................................................... 5 
1.2.2 Signaling pathway of Axl ....................................................................................................... 6 
1.2.3 Axl and melanoma .................................................................................................................. 7 
1.3 Akt3 ............................................................................................................................................... 8 
1.3.1 Akt3 ........................................................................................................................................ 8 
1.3.2 Signaling pathway of Akt3 ..................................................................................................... 8 
1.3.3 Akt3 and melanoma ................................................................................................................ 9 
1.4 A model of Axl signaling via activation of Akt3 ........................................................................ 10 
Hypothesis and aims .............................................................................................................................. 11 
Materials ................................................................................................................................................ 12 
2.1 Materials for Cell culture............................................................................................................. 12 
2.2 Materials for RT-PCR ................................................................................................................. 12 
2.3 Materials for Western blot ........................................................................................................... 13 
2.4 Materials for xCelligence ............................................................................................................ 14 
2.5 Materials for CRISPR ................................................................................................................. 14 
2.6 Materials for Flow cytometry ...................................................................................................... 15 
Methods ................................................................................................................................................. 16 
3.1 Cell culture .................................................................................................................................. 16 
3.1.1 General maintenance ............................................................................................................ 16 
3.1.2 Cell thawing ......................................................................................................................... 16 
3.1.3 Cell passaging ....................................................................................................................... 16 
3.1.4 Cell counting ........................................................................................................................ 17 
3.1.5 Cell freezing ......................................................................................................................... 17 
3.2 Analyzing Axl and Akt3 expression by RT-PCR ........................................................................ 17 
3.2.1 RNA isolation ....................................................................................................................... 17 
3.2.2 RNA precipitation ................................................................................................................ 18 
3.2.3 cDNA synthesis .................................................................................................................... 18 
3.2.4 RT-PCR ................................................................................................................................ 18 
3.3 Western blot ................................................................................................................................ 19 
3.3.1 Preperation of the gel............................................................................................................ 19 
3.3.2 Protein isolation .................................................................................................................... 20 
3.3.3 Western blot buffers ............................................................................................................. 21 
3.3.4 Western blot ......................................................................................................................... 22 
3.4 xCelligence .................................................................................................................................. 22 
3.4.1 Principle of xCelligence ....................................................................................................... 22 
3.4.2 Cell Proliferation analysis by xCelligence ........................................................................... 23 
3.4.3 Cell Migration analysis by xCelligence ................................................................................ 23 
3.4.4 Cell Invasion analysis by xCelligence .................................................................................. 24 
3.5 CRISPR ....................................................................................................................................... 25 
3.5.1 Principle of CRISPR............................................................................................................. 25 
3.5.2 Target selection of Human Axl ............................................................................................ 26 
3.5.3 Making of CRISPR construct ............................................................................................... 26 
3.5.4 Transform the plasmid into NEB 10-beta competent E.coli (C3019). ................................. 28 
3.5.5 DNA isolation for sequencing .............................................................................................. 28 
3.5.6 DNA isolation for transfection ............................................................................................. 29 
3.5.7 Transfection .......................................................................................................................... 29 
3.5.8 Brightfield and Fluorescence microscopy ............................................................................ 31 
3.6 Flow cytometry............................................................................................................................ 31 
3.6.1 Principle of flow cytometry .................................................................................................. 31 
3.6.2 Protocol ................................................................................................................................ 31 
3.7 Statistical analysis ....................................................................................................................... 32 
Results ................................................................................................................................................... 33 
4.1 Expression analysis of NZM cell lines ........................................................................................ 33 
4.1.1 Morphology of NZM cell lines ............................................................................................. 33 
4.1.2 Expression of Axl in the NZM cell lines. ............................................................................. 34 
4.1.3 Expression of Akt3 in the six NZM cell lines. ..................................................................... 36 
4.2 Cell function analysis of the six NZM cell lines by xCelligence system .................................... 38 
4.2.1 Proliferation .......................................................................................................................... 38 
4.2.2 Migration .............................................................................................................................. 41 
4.2.3 Invasion ................................................................................................................................ 42 
4.3 Axl knocking out by CRISPR ..................................................................................................... 44 
4.3.1 Target selection of Human Axl ............................................................................................ 44 
4.3.2 Sequence of CRISPR constract ............................................................................................ 45 
4.3.3 Transfection .......................................................................................................................... 46 
4.4 Analysis of Axl CRISP-knocking out by flow cytometry ........................................................... 47 
4.4.1 Axl knocking out analysis by flow cytometry after GFP sorting. ........................................ 47 
4.4.2 Time course analysis of Axl knock out by flow cytometry .................................................. 48 
Discussion ............................................................................................................................................. 49 
5.1 Culturing cells at atmospheric oxygen levels impacts cell function. ........................................... 49 
5.2 An important role for Axl in melanoma ...................................................................................... 49 
5.3 Axl contribution to drug resistance in melanoma. ....................................................................... 50 
5.4 Different roles for Akt3 played in melanoma. ............................................................................. 52 
5.5 The Axl-Akt3 signaling pathway may be important in melanoma metastasis. ........................... 53 
Conclusion ............................................................................................................................................. 54 
References ............................................................................................................................................. 55 
 
 
 
1 
 
Abbreviations 
 
Akt Protein kinase B (PKB) 
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MAPK  Mitogen-activated protein kinases 
MEK Mitogen-activated protein kinase kinase 
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STAT3 Signal transducer and activator of transcription 3 
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SDS Sodium dodecyl sulfate 
TALENs Transcription activator–like effector nucleases 
TEMED Tetramethylethylenediamine 
tracrRNA transactivating RNA 
ZFNs Zinc-finger nucleases 
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Abstract 
 
Melanoma is a highly invasive and metastatic cancer which can originate in skin, mucosa, 
uvea and leptomeninges. Although only 4% of skin cancers are melanomas, it leads to nearly 
80% of skin cancer-related deaths. Melanoma metastasizes quickly, and the median overall 
survival of metastatic melanoma is less than one year. Unfortunately, the under-lying 
biological mechanisms manipulating melanoma development and metastasis have not been 
clarified, thus understanding the mechanism of melanoma metastasis is a major issue. 
 The receptor tyrosine kinase Axl, which belongs to the TAM family, has a single ligand 
growth arrest–specific gene 6 (Gas6). Axl signaling enhances many essential biological 
functions for cancer progression by influencing cell transformation, proliferation, invasion, 
metastasis, survival, angiogenesis, and resistance to chemotherapeutic and targeting drugs. 
Furthermore, Axl correlates with cell migration and invasion in melanoma.  It is reported that 
about 40% of melanoma cell lines express high Axl levels, and the frequency of Axl 
expression increased with disease progression.  
The Akt family, which is the serine/threonine-specific protein kinase family, has three 
isoforms Akt1, Akt2 and Akt3, although they are closely related and highly conserved, it was 
revealed that they possessed distinct functions. Akt3 is the predominant isoform in 
melanomas where it plays a key role in melanoma development including invasion, metastasis 
and therapeutic resistance. 
The Axl-Akt3 co-expression is apparent in gene expression data sets, and Axl signaling 
regulates the EMT gene program by activating nuclear-localized Akt3 in breast cancer. A 
hypothesis model of Axl-dependent EMT gene program maintenance via activation of nuclear 
Akt3 was previously proposed by our research group indicating that Axl-Akt3 signaling may 
play an important role in breast cancer progression and Axl-Akt3 signaling pathway may 
become a novel therapeutic target to treat advanced breast cancer.  
In this study, the central hypothesis is that Axl affects melanoma metastasis via activation of 
Akt3, and the objectives including: characterize the role of Axl in metastatic melanoma; 
elucidate the mechanism for how Axl-Akt3 signaling affects metastasis in melanoma and 
validate the central hypothesis. 
New Zealand Melanoma cell lines were obtained from Dr. Bruce Baguley (Auckland, NZ). 
QPCR and Western blot analysis was performed to measure the Axl and Akt3 expression.  
xCelligence system, an electronic real-time cell-sensing assay (RTCA), was used to analyze 
the cell functions including proliferation, migration and invasion (Matrigel); all the function 
analysis experiments were performed twice with the RTCA station separately in a normal 
incubator with atmospheric oxygen tension (21% O2) and a low oxygen incubator with 
physiological oxygen tension (5% O2); in migration assay we use higher FBS concentration to 
stimulate cells migrating; in invasion assay, we coated the CIM-Plate with matrigel and 
stimulated cells moving with different FBS concentration. Axl and Akt3-targeting CRISPR-
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Cas9 plasmids were constructed (with D. Micklem) and sequence verified. Transfection was 
performed by Neon transfection system and analyzed by fluorescence microscopy. 
We demonstrated that among our six New Zealand Melanoma cell lines, cells with higher 
expression of Axl have higher levels of proliferation, migration and invasion; Cells with 
higher expression of Akt3 also have higher abilities of proliferation and migration, but have 
the lowest invasion ability without co-expression of Axl. We found that cells kept in normal 
incubator (atmospheric, 21% O2) and in low oxygen incubator (physiological, 5% O2) showed 
different proliferation and invasion abilities, but similar migration level. In order to elucidate 
how Axl signaling contributes melanoma metastasis we tried to permanently knock out the 
gene coding for Axl using CRISPR-Cas9 system.  However, so far we have not been able 
knock out the gene coding for Axl using this system in NZM17 cells.  
In conclusion, Axl and Akt3 expression varied in among the New Zealand Melanoma cell 
lines. The Axl-Akt3 co-expressing NZM17 cells show consistent proliferation, migration and 
invasion abilities both physiological oxygen tension. NZM cells cultured at different oxygen 
tensions show differences in proliferation migration and invasiveness. Isolation of Axl 
CRISPR knock out NZM cell lines is in progress. These results support new therapeutic 
approaches based on Axl signaling inhibition to treat metastatic melanoma.  
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Introduction 
1.1 Melanoma 
1.1.1 Melanoma 
Melanoma is a highly invasive and metastatic cancer which can originate in skin, mucosa, 
uvea, and leptomeninges [1]. Although only 4% of skin cancers are melanomas, it leads to 
nearly 80% of skin cancer-related deaths [2]. The incidence of melanoma has continued to 
increase, which made melanoma become the 5th most common cancer in men and the 6th 
most common in women [3]. Besides, according to the World Health Organization, about 
132,000 new cases of malignant melanoma are diagnosed globally each year and the number 
is increasing at a faster rate than any other forms of cancer [4, 5].  At the same time, the 
mortality rate of melanoma also sharply increased in the last ten years worldwide [6]. Norway 
is actually worse off in this respect, as Norway has a higher mortality rate than countries with 
similar incidence rates, and has the same mortality rate as Australia, where the incidence rate 
is 2x of the Norwegian [7, 8]. Operative treatment of early-stage melanoma brings about a 
cure rate of 90%, but the average five-year survival rate of metastatic melanoma is around 
11%, and the median survival rate is about 6 to 12 months [9]. The etiology and pathogenesis 
of melanoma is not yet fully known, some risk factors for the development of melanoma 
include sun exposure [10], presence of atypical nevi [11, 12], skin pigmentation phenotype 
[11], personal [12] and family histories [11] of melanoma. The most noteworthy part is the 
role of sun exposure and skin pigmentation phenotype, as they are well established risk 
factors. Intermittent intense sun exposure increases risk of melanoma and as opposed to 
chronic sun exposure that increases risk of other skin malignancies. 
1.1.2 Metastatic melanoma 
Cancer metastasis is the cause of approximately 90% of tumor deaths [15]. According to the 
‘‘seed and soil’’ hypothesis, cancer metastatic cells function as ‘‘seeds’’ and a particular 
organ microenvironment or niche serves as the ‘‘soil’’ [16]. It is a multistep cascade requiring 
diverse biological processes, including local invasion/matrix remodeling, 
intravasation/extravasation, survival in circulation, and colonization, survival, and growth in 
secondary sites [17].  
Melanoma metastasis is also a complex process requiring melanoma cell detachment from the 
primary tumor and migration to secondary sites in the body through the lymphatic or blood 
circulatory systems [18, 15]. Melanoma has the propensity to spread throughout the body 
even at early stages of tumorigenesis [19]. Staging of primary melanomas together with 
histopathological features such as thickness, mitotic index, ulceration, and lymph node status 
are generally prognostic of clinical outcome [20–24]. However, when melanoma cell 
dissemination occurs from primary tumors, it is difficult to diagnosis. Besides even patients 
with localized melanoma are diagnosed at stage I or II, approximately 7% or 30% will suffer a 
recurrence [25], and most will then progress to metastatic disease and eventual death [26]. 
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Metastasis is the essential event dictating poor outcome for patients diagnosed with a 
localized primary melanoma. 
1.1.3 The treatment of melanoma 
The treatments of melanoma include surgery, chemotherapy, immunotherapy, and radiation 
therapy [27], however it is well known that melanoma is characteristically refractory to 
current therapies, so new approaches and therapies are needed to raise the life expectancy of 
patients with metastatic melanoma. In recent years, based on the improved understanding of 
genetic and molecular mechanism of melanoma, many new drugs were approved for 
treatment of advanced melanoma, including T-cell regulatory immune therapies for example 
the human anti-cytotoxic T lymphocyte antigen-4 monoclonal antibodies (ipilimumab) [28], 
anti-programmed death-1 (PD-1) antibodies (pembrolizumab, nivolumab) [29] and targeted 
therapies against MAPK pathway for example BRAF inhibitors (vemurafenib, dabrafenib) [30, 
31], MEK inhibitor (trametinib) [32] and recently the combination of BRAF and MEK 
inhibitors (dabrafenib with trametinib) [33]. 
In particular, because 50% of melanomas have mutations in BRAF and up to 20% of 
melanomas have mutations in the NRAS gene in a mutually exclusive way with BRAF [34], 
there has been remarkable progress for the BRAF mutant subset of melanoma with the 
development of the selective BRAF and MEK inhibitors. For example,  BRAF inhibitors 
alone produce response rates in the range of 40-50% with a median progression-free survival 
(PFS) of 6-7months [30, 31]; MEK inhibitor trametinib demonstrated significantly improved 
response rates (22 vs 8%) median PFS (4.8 vs 1.5 months) and 6-month overall survival (OS) 
(81 vs 67%) compared with chemotherapy in a Phase III clinical trial [32]; the combination of 
BRAF with MEK inhibitors resulted in more frequent responses and improved PFS and OS 
compared to BRAF inhibitors alone [33,35,36]. However, they all acquired resistance which 
seriously influenced the results of treatment, besides selection and appropriate sequencing of 
these drugs still remained challenging, following more research work of treatment is still 
eagerly needed. 
1.2 Axl 
1.2.1 Axl 
The receptor tyrosine kinase Axl, which is a transmembrane receptor, was first identified as a 
transforming gene in chronic myeloid leukemia from two patients [37]. Axl, also called Ark 
and Ufo, contains an intracellular (C-terminal) kinase domain including three 
autophosphorylation sites (Tyr779, Tyr821, and Tyr866) and a unique extracellular (N-
terminal) domain composed of two N-terminal immunoglobulin-like domains and two 
fibronectin type III repeats similar to the structure of neural cell adhesion molecules [38, 39]. 
Together with Tyro-3 and Mer, Axl belongs to the TAM family which has two ligands 
including protein S and the growth arrest–specific gene 6 (Gas6) [40], and Gas6 which is 
dependent on vitamin K has the highest affinity to Axl. Activation of Axl occurs after the 
binding to Gas6 [41; 42] 
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Previous studies have demonstrated that Axl has the oncogenic activity. It was reported that 
activation of Axl signaling by its ligand Gas6 leads to enhanced proliferation, survival, 
invasion, and metastasis of cancer cells. Furthermore Axl was found deregulated in several 
types of cancer, such as prostate [43; 44], breast [45], lung [46-48], leukemia [49; 50], and 
esophageal adenocarcinomas [49], and it has been shown to play a role in the epithelial–
mesenchymal transition (EMT), which is also an important feature for the initiation of 
metastasis [51-55]. For example, in hepatocellular carcinoma (HCC), Axl was found up-
regulation in situ hybridization and a further study suggested that Axl acts downstream of the 
Hippo pathway to trigger cell invasion and metastasis [56, 57]; in breast carcinoma,  autocrine 
activation of Axl is reported essential for EMT and metastatic dissemination [52] and 
antagonizing Axl signaling inhibits pulmonary metastasis [45]. Besides overexpression of Axl 
is correlated with poor survival of tumor patients [58] and is also linked to an increase in 
resistance to various drug treatments [59-60]. For instance, imatinib-resistant gastrointestinal 
stromal tumors, nilotinib-resistant chronic myeloid leukemia cells, BMS-754087–resistant 
rhabdomyosarcoma, erlotinib-resistant EGFR-mutant lung cancer and lapatinib-resistant 
HER-2–positive breast tumor cells are all reported to link with increased Axl expression level 
[59-60; 63-65]. In this way, it also means that inhibition of Axl may prevent or overcome 
acquired resistance to certain drugs. 
1.2.2 Signaling pathway of Axl 
Axl signaling enhances many essential biological functions for cancer progression, chronic 
immune disorders and cardiovascular diseases by influencing cell transformation, proliferation, 
invasion, metastasis, survival, angiogenesis, and resistance to chemotherapeutic and targeting 
drugs [66-67]. Because Gas6 has the highest affinity for Axl among the TAM receptors [41-
42], it is often called the Gas6/Axl pathway, which has been predominantly studied in cancer 
[67; 68]. Adequate evidence supported that the downstream pathways activated by the 
Gas6/Axl signaling include the phosphatidylinositol 3-kinase (PI3K)/Akt pathway [69], 
MAPK/extracellular signal-regulated kinase (ERK) pathway [70], and NF-κB pathway [71].  
Several reports highlighted that PI3K/Akt pathway is the important downstream pathway 
activated by the Gas6/Axl signaling [72,73], which is involved in many cellular processes 
including proliferation, differentiation, apoptosis, cell cycle progression, cell motility and 
tumorigenesis, tumor growth, and angiogenesis [74, 75]. In addition, it is also reported that 
targeting PI3K/Akt inhibits proliferation and tumorigenesis of human cancer [73]. Besides, 
Xu J et al. found that Axl had a critical role in the PI3K/Akt-PAK1 signal pathway and 
knockdown of it inhibits the metastasis properties of hepatocellular carcinoma [76]. The 
implications of Axl and Akt in cancer progression have been reviewed by Korshunov, V.A. 
[67], where he suggests that activation of PI3K and its downstream target is a central step in 
Axl-dependent signal transduction. (Figure 1) 
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Figure 1: Axl receptor signal transduction. Axl signaling pathway controls biological 
functions such as inflammation, migration, survival and proliferation via activating STAT1, 
PI3K, Grb3 and other downstream proteins. Adapted from Reference [67]. 
 1.2.3 Axl and melanoma 
The role for Axl in melanoma has been studied for many years, however the importance of 
which has not been clearly elucidated. Sensi et al. have reported that 22 of 58 of cell lines 
(38%) in a melanoma progression panel were detected with high Axl expression, and they 
also found that the frequency of Axl expression increased with disease progression. Besides 
they found that Axl promoted tumor cell migration and invasion. Furthermore, knockdown or 
pharmacological inhibition of Axl using the selective inhibitor R428 showed comparable 
effects in reducing migration and invasion [77]. However, according to their research, Axl 
depletion did not dramatically affect proliferation [77].  
In accordance to Sensi et al., Tworkoski et al. reported that inhibiting Axl function in a high 
Axl-expressing melanoma cell line with short interfering RNAs or a pharmacological 
inhibitor led to reduced invasion and migration [78]. However, in contrary to Sensi et Al., 
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their data indicates that knockdown of Axl inhibits proliferation in some lines [77, 78]. All the 
results indicate that Axl may play an important role in melanoma metastasis, thus 
understanding the mechanism of how Axl affects melanoma metastasis is a major issue. 
 
1.3 Akt3 
1.3.1 Akt3 
The Akt family, which is the serine/threonine-specific protein kinase family, has three 
isoforms Akt1, Akt2 and Akt3, they are encoded by different genes, but share a conserved 
domain structure consisting of an N-terminal pleckstrin homology domain, a kinase domain 
and a C-terminal regulatory domain containing a hydrophobic motif [80]. Although they are 
closely related and highly conserved, it was revealed that they possessed distinct functions in 
cancer models [81, 82]. Akt1 is ubiquitously expressed and is essential for growth [83, 84]; 
Akt2 is primarily expressed in insulin-responsive tissues and is essential for cell survival, 
growth and glucose homeostasis [83, 85]; Akt3 is highly expressed in brain and testes, and is 
essential for maintenance of brain homeostasis [83, 86, 87]. 
Akt3 is located at chromosome 1q44 and encodes the 479 amino acid [88]. Interestingly, 
about Akt3 there are different results reported in tumor progression, some believe that Akt3 
can enhance tumor development. For example, recently, Turner, K. M et al. identified Akt3 as 
the dominant Akt isoform that robustly stimulates glioma progression, besides they also 
discovered key roles for Akt3 in activating DNA repair pathways, which led to enhanced 
survival of human glioblastoma cells following radiation or temozolomide treatment [89]. In 
contrast, there are also some evidences suggesting that Akt3 exerts inhibitory effects in cancer 
[83], for instance, it is reported that Akt3 has been shown to inhibit lung tumor growth in 
mice; inhibiting Akt3 can lead N-Cadherin to promote breast cancer metastasis [90–92]. 
1.3.2 Signaling pathway of Akt3 
The PI3K/Akt pathway serves as a key factor in the regulation of cancer cell invasion and 
metastasis [93]. Akt3 was involved in PI3K and MAPK signaling pathway which can regulate 
cell senescence, proliferation and apoptosis. Besides, loss of Phosphatase and tensin homolog 
(PTEN) leads to increased levels of Phosphatidylinositol (3,4,5)-trisphosphate (PIP3) then 
increased activity of Akt3 [94-96]. The activated Akt3 inhibits apoptosis and induces 
proliferation by phosphorylation of substrate proteins (Figure 2) [97].  Furthermore, 
decreased apoptpsis makes melanoma cells less sensitive to chemotherapeutic drugs which 
function through this mechanism [97]. 
Recently, Akt3 and V600E BRAF have been cooperatively shown to promote melanoma 
development. Akt3 reduces its and MAPK pathway activity by phosphorylating mutant 
V600E BRAF in order to promote rather than inhibit growth. In other words, activating 
V600E BRAF mutation initially promotes nevi development, but the resulting high, intense 
activation of the MAPK pathway inhibits further tumor progression requiring Akt3 activation 
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to phosphorylate V600E BRAF to bypass this barrier and promote melanoma development 
[98]. 
 
Figure 2: Akt3 was involved in PI3K and MAPK signaling pathway which can regulate cell 
senescence, proliferation and apoptosis.  Adapted from Reference [97]. 
1.3.3 Akt3 and melanoma 
Akt3 is the predominant isoform in melanomas where it plays a key role in melanoma 
development including invasion, metastasis and therapeutic resistance [96, 99]. Increased 
Akt3 expression/activity occurs in 60–70% of sporadic melanomas [96, 100] and also plays a 
significant role in progression to more advanced aggressive tumors [101, 94, 96]. The 
function of Akt3 in melanoma was widely studied, for example, an experimental tumor 
progression model in which Akt3 activity in melanocytes was compared with low passage cell 
lines from primary melanoma tumors at the radial and vertical stages of cell growth, revealed 
that Akt3 activity increased in the radial growth phase and remained elevated in comparison 
to Akt1 and Akt2. The high level of involvement in advanced melanomas leads to the 
inference that Akt3 activation performs critical functions in melanoma development [94, 96]. 
Acquisition of Akt3 activity facilitates the progression of quiescent melanocytic nevi into 
aggressive vertical and metastatic stages by inhibiting V600E BRAF activity thereby 
releasing cells from senescence block [97]. 
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1.4 A model of Axl signaling via activation of Akt3 
 
Recently, Tiron et al.in our research group proposed a hypothesis model of Axl-dependent 
EMT gene program maintenance via activation of nuclear Akt3 (Figure 3) [102]. This 
hypothesis model was based on breast cancer. They found that Akt3 was upregulated by EMT 
and required for Axl-dependent regulation of mammary stem cell traits, besides they also 
concluded that EMT and stem cell functions required Axl-dependent activation of nuclear 
targeted Akt3 [102]. In this hypothesis model, Axl and Akt3 expression are induced by micro-
environmental factors and establish a novel signal transduction pathway activated by 
paracrine sources of Gas6. Their results implicated the Axl-Akt3 signaling pathway may 
become a novel therapeutic target to treat advanced breast cancer. 
 
 
 
 
Figure 3: Hypothesis model of Axl affect cell functions via activation of Akt3. This 
hypothesis model was based on breast cancer. Adapted from Reference [102]. 
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Hypothesis and aims 
 
The central hypothesis is that Axl affects melanoma metastasis via activation of Akt3. 
 
The aims of the study are: 
 
Aim 1  Characterize Axl in metastatic melanoma. 
 
Aim 2  Elucidate the mechanism for how Axl-Akt3 signaling  affects metastasis in 
melanoma. 
 
Aim 3  Validate whether the hypothesis model based on breast cancer (Figure 3) 
works in metastasis melanoma. 
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Materials 
2.1 Materials for Cell culture 
The 6 New Zealand Melanoma cell lines were generated from surgical samples of metastatic 
melanoma. Written consent was obtained from all patients under Auckland Area Health Board 
Ethics Committee guide lines [101, 102]. 
Table 1:  Materials for Cell culture 
Material Supplier 
MEM Alpha (1×) Life technologies 
FBS-HI (Fetal Bovine Serum) Sigma 
Transferrin Sigma 
Sodium Selenite Sigma 
Insulin Sigma 
Penicillin-Streptomycin Sigma 
Trypsin-EDTA solution Sigma 
PBS Sigma 
DMSO Sigma 
 
2.2 Materials for RT-PCR 
 
Table 2: Materials for RT-PCR 
Material Supplier 
Nuclease-free Water Ambion by Life technologies 
Glycogen Ambion by Life technologies 
Lithium chloride Merck 
Ethanol Sigma 
Axl primer Applied Biosystems 
Akt3 primer Applied Biosystems 
Human β-actin (20×) Life technologies 
Human 18S rRNA(20×) Life technologies 
LightCycle 480 Probes Master Roche 
 
Table 3: Kits for RT-PCR 
Material Supplier 
RNeasy Mini Kit (50) QIAGEN 
High Capacity cDNA Reverse Transcription 
Kit 
Applied Biosystems 
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2.3 Materials for Western blot 
 
Table 4: Materials for protein isolation and measurement 
Material Supplier 
NP40 Life technologies 
Sodium dodecyl sulfate solution(SDS) Sigma 
Nadoc Sigma 
Trizma base Sigma 
Sodium chloride Sigma 
Aprotinin Sigma 
Leupeptin Sigma 
Natrium Vanadat Sigma 
PMSF Merck 
BCA protein assay kit Thermo 
 
Table 5: Materials for gel preparation 
Material Supplier 
30% Acrylamide/Bis Solution Bio-Rad Laboratories 
Trizma base Sigma 
Sodium dodecyl sulfate solution(SDS) Sigma 
Ammonium  persulfate Sigma 
TEMED Sigma 
 
Table 6: Materials for Western blot buffer 
Material Supplier 
Trizma base Sigma 
Sodium chloride Sigma 
Sodium dodecyl sulfate solution(SDS) Sigma 
Glycine Sigma 
Tween-20 Sigma 
Blotting-Grade Blocker Bio-Rad Laboratories 
Methanol Sigma 
 
Table 7: Materials for Western blot 
Material Supplier 
Precision Plus Protein Standards Bio-Rad Laboratories 
Margic Mark XP Western Protein Standards Life technologies 
PVDF Transfer Membrane GE Healthcare 
Pierce ECL Western Blotting Substrate Thermo 
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Table 8: Antibodies used for Western blot 
Material Supplier 
Human Axl Antibody (AF154) R&D systems 
Anti-Akt3/PKBγ Antibody (05-780) Merck Millipore 
GAPDH (6C5) (sc-32233) Santa Cruz Biotechnology 
goat anti-mouse IgG-HRP (sc-2005) Santa Cruz Biotechnology 
donkey anti-goat IgG-HRP (sc-2056) Santa Cruz Biotechnology 
Phopho-Axl (Tyr702) (D12B2) Rabbit mAb Cell signaling 
HRP-Goat Anti-Rabbit IgG (H+L) Invitrogen 
 
2.4 Materials for xCelligence 
 
Table 9: Materials for xCelligence 
Material Supplier 
Matrigel BD Biosciences 
Trypsin Neutralizing Solution Cell Applications, Inc 
CIM-Plate 16 Roche 
E-Plate VIEW 16 ACEA Biosciences 
 
2.5 Materials for CRISPR 
 
Table 10: Materials for CRISPR and Sequence 
Material Supplier 
BG204: pSqCas9(BB)-2A-GFP BerGenBio 
Oligo 1: DL315 HsAxlEx7 afor IDT 
Oligo 2: DL316 HsAxlEx7 arev IDT 
Oligo 3: DL317 HsAxlEx7 bfor IDT 
Oligo 4: DL318 HsAxlEx7 brev IDT 
10× T4 Ligation Buffer New England Biolabs 
T4 Polynucleotide Kinase New England Biolabs 
10×FastDigest Buffer Thermo Scientific 
FastDigestBpil Thermo Scientific 
T7 DNA Ligase New England Biolabs 
C3019 (10-beta Competent E.coli) New England Biolabs 
LB medium Sigma 
LB Agar Tablets Sigma 
BigDye 3.1 Life technologies 
5× Sequence Buffer Life technologies 
PBS,1× (without calcium and magnesium) Cellgro 
QIAprep Spin Miniprep Kit (50) QIAGEN 
Plasmid Midi Kit (100) QIAGEN 
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Neon 10µl Kit Invitrogen 
 
2.6 Materials for Flow cytometry 
 
Table 11: Antibodies and materials for flow cytometry 
Material Supplier 
Formaldehyde Solution Sigma 
Bovine Serum Albumin Sigma 
Human Axl Antibody (AF154) R&D systems 
Alexa Fluor 647 donkey anti-goat IgG (H+L) Life technologies 
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Methods 
 
3.1 Cell culture 
3.1.1 General maintenance  
The six New Zealand melanoma (NZM) cell lines used for this study were generated from 
surgical samples of metastatic melanoma [103, 104]. Written consent was obtained from all 
patients under Auckland Area Health Board Ethics Committee guidelines. NZM cell lines 
were cultured in α-modified minimal essential medium supplemented with insulin (5 μg/ml), 
transferring (5 μg/ml), and sodium selenite (5ng/ml), 100 U/ml of penicillin, 100 μg/ml of 
streptomycin (PS), 5% fetal bovine serum (FBS). Instead of culture cells in incubators where 
the oxygen tension corresponds to atmospheric levels (21% O2) like common practice work in 
vitroit was noteworthy that in this study the NZM cell lines were kept in a low oxygen 
incubator (5% O2, 5% CO2, 37 °C) in order to mimic physiologically low oxygen levels in 
tumors. Although it was not the usual way of culturing cells, but it was a key point in this 
study. 
The NZM cells cultured in T75 flasks and were daily observed by microscope of Nikon 
ECLIPSE TS100. After installing a Nikon D3000 camera on this microscope and switching to 
photo format, the pictures were taken by Nikon D3000. 
3.1.2 Cell thawing 
Medium was pre-warmed in a 37°C water bath for 30 minutes. The cryovials containing NZM 
cells were removed from liquid nitrogen storage and were immediately placed into the 37°C 
water bath. When only a small bit of ice left, the vials were transferred into the flow hood. 
Before opening, the vials were wiped with 70% ethanol. The contents of each vial of cells 
were transferred to T-25 culture flasks containing 5 ml of medium, and then the flasks were 
put into a low oxygen incubator (5% O2, 5% CO2, 37 °C). The medium was changed with 
fresh medium after 4 hours. When cells reached about 80% confluence, which were 
transferred into T-75 flasks where cells were kept in culture. 
3.1.3 Cell passaging 
The cells were routinely passaged (every 2-3 days) after reaching approximately 70-90% 
confluency. Medium, 1×PBS and trypsin-EDTA were pre-warmed in 37°C water bath for 30 
minutes before passaging. First, medium was removed, and cells were washed by 3 ml 1×PBS, 
then added 3 ml trypsin. After about 2-3 minutes incubating in incubator, the cells were 
observed under a light microscope. The side of flask was hit several times until cells were 
completely detached from substratum then 3 ml fresh medium was added to stop trypsin. The 
cell suspension was transferred into a 15ml tubes, and centrifuged at 1200 rpm for 5 minutes. 
The supernatant was removed and fresh medium was added. After suspending, cells were 
diluted 1:4 and transferred into new T-75 flask with 10ml fresh medium. The flasks were put 
back into low oxygen incubator.  
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3.1.4 Cell counting 
Cell counting was performed by Millipore's Scepter handheld automated cell counter with 
60μm sensors. Cells were harvested and suspend as described before, and transferred into a 
1.5 mL Eppendorf tube.  After the Scepter cell counter was turned on, and a 60μm sensor was 
attached to the end of the counter with the electrode sensing panel facing toward the front of 
the instrument. Because Scepter sensors consist of a precision molded sampling chamber, 
with an electronic sensing zone and integrated cell-sensing electrodes, it is possible to 
discriminate cell size at sub-micron resolution, and cell volume at sub-picoliter resolution. 
The plunger was depressed when it showed "Hold down the plunger to begin", then the sensor 
was submerged into the cell suspension solution and the plunger was released to aspirate the 
cell suspension into the sensor. When "Count Complete. Please remove sensor and discard." 
was displayed on the screen, the sensor was removed and the cell data was read. 
3.1.5 Cell freezing 
Cell lines in continuous culture are more easily to surfer genetic drift, senescence, microbial 
contamination and so on, so it is vitally important that they are frozen down and preserved for 
long-term storage. First, cells were washed, trypsinized, counted and centrifuged at 1200 rpm 
for 5 minutes when they are reached 70-90% confluence. Second the freezing medium was 
mix by 70% α-modified minimal essential medium, 20% FBS and 10% DMSO. Cells were 
resuspended in moderate freezing medium to create a cell concentration of 1×106 cells per ml. 
Then the cell freezing mixture was transferred into storage vials at 1 ml per cryovial. After 
labeled with name, passage number and date, cells were immediately transferred to -20°C for 
one hour, followed by -80°C overnight and then permanent storage in liquid nitrogen. 
3.2 Analyzing Axl and Akt3 expression by RT-PCR 
3.2.1 RNA isolation 
RNA isolation was performed using RNeasy Mini Kit (50) according to the instruction. Cells 
for RNA extraction were cultured in 60mm dishes. When cells reached 70-90% confluence, it 
is ready for RNA isolation. First medium was aspirated completely, and cells were washed 
twice by PBS. Cells were disrupted by adding 600 µl RLT buffer, and then scraped and 
homogenized. After 600 µl of 70% ethanol was added, 700 µl well mixed lysate was 
transferred to RNeasy spin column which was placed in a 2 ml collection tube, then 
centrifuged at 10,000rpm for 15s, the flow-through was discarded. Secondly 700 µl buffer 
PW1 was added to the spin column and centrifuged as described above to wash the column 
membrane. After discarding the flow-through, 500 µl RPE buffer was added to the spin 
column, and centrifuged as above. Similarly the flow-through was discarded. Thirdly, 500 µl 
buffer RPE was added again, but centrifuged at 10,000 rpm for 2 minutes. After that, the 
RNeasy spin column was placed in a new 2 ml collection tube and centrifuged at full speed 
for 1 minute. Finally, the RNeasy spin column was transferred in a new 1.5 ml Eppendorf 
tube. After adding 30 µl of RNase-free water, it was centrifuged at 10,000rpm for 1 min to 
elute the RNA. 
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3.2.2 RNA precipitation 
The RNA isolated from above was added with 1.5 µl Glycogen, 1.9 µl 8M Lithium chloride 
and 83.5 µl (2.5 volume) 100% ethanol, and then be frozen at -20 ºC overnight. The next day, 
it was spanned down for 30 min at full speed. After removing ethanol carefully, 500 µl of 70% 
ethanol was added and then it was spanned for 5 min at the same speed. Finally the ethanol 
was aspirated and the tube was dried in air for about 20 min. The RNA pellet was dissolved in 
30 µl RNase-free waster, and measured by Nanodrop. 
3.2.3 cDNA synthesis 
cDNA making was performed using High Capacity cDNA Reverse Transcription Kit. Firstly 
200 ng RNA sample was prepared in 10µl according to the concentration. Secondly 10 µl 
mastermix was mixed by adding 2µl 10× RT buffer, 0.8 µl 25× dNTP Mix 100mM, 2 µl 10× 
RT random primers , 1µl reverste tanscriptase and 4.2 µl RNase-free water. Thirdly 10 µl 
RNA sample and 10 µl mastermix were mix together and transferred in thermal cycler with 
the loading program 25ºC for 10min, 37ºC for 120min, 85ºC for 5min and 4º for holding. 
cDNA can be stored in -20ºC freezer. 
3.2.4 RT-PCR 
An optimal RT-PCR assay is absolutely essential for accurate and reproducible quantification 
of the samples. Therefore we first optimized our RT-PCR assay by performing serial dilutions 
of the templates and making standard curves. The primers and probes were validated for each 
target and the individual efficiencies were determined. In this part, Light Cycle 480 system 
was used to test gene expressing. The reaction (totally 10 µl) was mixed by 5µl Roche 
Mastermix, 2 µl RNase-free water, 0.5 µl reference probe including Human 18S rRNA(20×) 
or Human β-actin (20×), 0.5 µl Axl or Akt3 probe and cDNA template 2 µl. The cDNA 
template was diluted as 1:1, 1:10, 1:100, and 1:1000 in RNase-free water, and each sample 
was prepared four duplicates. The mixture was loaded in a 384 well plate and then transferred 
to Light Cycle 480 system with program as in Table 12. The crossing point (CP) value which 
was a cycle number in a log-linear region was used to calculate the quantitative value of RT-
PCR. Based on the data, the standard curves were generated, and the amplification 
efficiencies of our samples were between 95%-105%. 
After validation, we determined to use two reference genes, human beta-actin and human 18s 
RNA and evaluated at two concentrations 1:10 and 1:100. The reaction (totally 10 µl) was 
mixed as above: 5µl Roche Mastermix, 2 µl RNase-free water, 0.5 µl reference probe 
including Human 18S rRNA(20×) or Human β-actin (20×), 0.5 µl Axl or Akt3 probe and 
cDNA template 2 µl. Each sample was prepared three duplicates. The mixture was loaded in a 
384 well plate and then transferred to Light Cycle 480 system with program as in Table 12. In 
quantitative analysis, we used the CP value of Axl or Akt3 to divide CP value of reference 
gene, then the data was collected and calculated for mean value, and the analysis figure was 
made based on the mean value with standard error by Excel 2010. 
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Table 12: Program setting of RT-PCR with Light Cycle 480 system 
Thermal cycling conditions 
Stage Temp. (ºC) Time (mm:ss) 
Pre-incubation 95 10:00 
Amplification (45 cycles) 
Amplification-1 95 00:10 
Amplification-2 60 00:30 
Amplification-3 72 00:01 
 
Cooling 40 00:30 
 
3.3 Western blot 
3.3.1 Preperation of the gel 
The concentration of gel is determined by aim protein size. According to the size of our aim 
protein including Axl (140 kDa) and Akt3 (56 kDa), 10% SDS-PAGE gel was chosen as 
separating gel, and 4% as stacking gel. Firstly glass plates were cleaned and dried, after fixing 
the glass plates well water was filled between the plates and standed for 30 min to check 
whether it was clogged. Secondly ingredients were mixed as Table 13 except 10% 
ammonium persulfate and TEMED, for they need to be added in just before.  After 30 min 
water was removed and the plates were dried by filter paper if it didn’t leak. At this time, the 
last ingredients, 10% ammonium persulfate and TEMED, were added and mixed with other 
ingredients then added between layers. After 30-45 min gel was stiff then added stacking gel. 
Stacking gel making was the same with separating gel, and the materials form was Table 14. 
Gel could be kept in running buffer (stated below) in 4ºC for about one month. 
Table 13:  10% separating gel making solutions 
10% Separating gel (1.5mm) 
30% Acrylamide/Bis Solution 3.33ml 
1.5M Tris ph8.8 2.5ml 
MilliQ H2O 4ml 
10% SDS 100µl 
10% ammonium persulfat 50µl 
TEMED 5µl 
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Table 14: 4% Separating Gel making solutions 
4% Separating gel (1.5mm) 
30% Acrylamide/Bis Solution 670µl 
0.5M Tris ph6.8 1.25ml 
MilliQ H2O 3ml 
10% SDS 50µl 
10% ammonium persulfat 50µl 
TEMED 5µl 
3.3.2 Protein isolation 
In this part, we chose NP-40 RIPA buffer as lysis buffer, it was made as Table 15-16. 
 
Table 15: NP-40 Ripa buffer making solutions 
Solution Composition  Volume  
NP40 1% 10ml 
10% SDS 0.1% 10ml 
Nadoc 0.5% 5g 
1M Tris ph7.4 50mM 50ml 
5M Nacl 150mM 30ml 
H2O  868ml 
Total  1L 
 
Table 16: RIPA lysis buffer making solutions 
Solution Composition 
Aprotinin (1µg/µl) 1µl 
Leupeptin (1µg/µl) 1µl 
Natrium Vanadat 100el 200mM 10µl 
PMSF 100mM 10µl 
NP-40 RIPA  Lysis buffer 978µl 
Total 1ml 
 
Cells for protein isolation were cultured in T75 Flask until they reached 70-90% confluency. 
Medium was removed and the cells were washed by PBS. 500 µl of RIPA buffer were added. 
After 1-2 min cells were scraped and transferred to a 1.5 Eppendorf tube. It was centrifuged at 
full speed for 5 min at 4 °C. Final the lysate was transferred to a new Eppendorf tube and 
prepared for measurement. The protein sample could be stored at -20 °C. 
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3.3.3 Western blot buffers 
 
In Western blot, different kinds of buffer were needed including running buffer, transfer 
buffer, washing buffer and blocking buffer. All the buffers were made as following forms 
(Table 17-20): 
 
Table 17: Running buffer making solutions  
Running buffer 10× 1L 
Solution Composition 
Tris (Mw=121.14) 30.3g 
Glysine (Mw=75.07) 144g 
20% SDS 10g(50ml) 
MilliQ H2O 1L 
Running buffer 1× 1L 
Running buffer 10×  100ml 
MilliQ H2O 900ml 
 
Table 18: Transfer buffer solutions (store at 4°C) 
Transfer buffer 10× 1L 
Solution Composition 
Tris (Mw=121.14) 30.3g 
Glysine (Mw=75.07) 144g 
MilliQ H2O 1L 
Transfer buffer 1× 2L 
Transfer buffer 10× 200ml 
100% Methanol 400ml 
MilliQ H2O 1400ml 
 
Table 19: Washing buffer solutions  
Washing buffer TBS 20× 2L (PH 7.6) 
Solution Composition 
Tris (Mw=121.14) 96.8g 
NaCl 320g 
MilliQ H2O 1.5L ( adjust PH with HCl) 
Washing buffer TBST 1× 1L 
Washing buffer TBS 20× 50ml 
Tween-20 1ml 
MilliQ H2O 950ml 
 
Table 20: Blocking buffer solutions  
Blocking buffer 
Solution Composition 
Marvel Milk powder 2.5g 
Washing buffer TBST 1× 50ml 
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3.3.4 Western blot 
According to the concentration of protein samples, each sample was contained 20 µg protein, 
sample loading buffer 8.75 µl and MilliQ H2O until the total reached 35 µl. All the samples 
were mixed well and boiled at 90 °C for 5 min. Marker was mixed with 3.5 µl Magic marker 
and 8 µl protein standard. After loading sample into the wells of SDS-PAGE gels, the gels 
electrophoresis ran at 90V for about 70 min. When protein separation was down, transfer 
sandwiches were made by sponges, filter paper, gel and Nitrocellulose membrane activated 
with Methanol. The cassettes were placed in tankers with ice, and ran at 100V for 60min. 
After transferring the membranes were blocked in blocking buffer for 60 min. Antibodies 
Human Axl Antibody (1 µg/ml), Anti-Akt3/PKBγ Antibody (1:1000) and Phospho-Axl 
(Tyr702) Antibody (1:1000) were diluted in 1× TBST, and the membranes were incubated in 
antibodies at 4 °C overnight. 
The membranes were washed by TBST 4×5 min, and incubated with 2° antibodies for 90 min 
at room temperature. After washing as before, the membranes were transferred into Super 
Signal West Femto Maximum Sensitivity Substrate (mixed 1:1) and were ready for imaging. 
The images were acquired by ChemiDoc™ XRS+ System with Image Lab™ Software. After 
that, membranes were incubated with the GAPDH antibody at 4°C overnight, and then 2° 
antibody and imaged as above. Then images were analyzed by software of Image Lab 3.0.  
In quantitative analysis, after aim bands were found and adjusted, the sum of all intensities 
within the band boundaries showed with Volume (Int) value was calculated by quantitative 
tools in the software. Then the Int value of Axl , phosphor-Axl or Akt3 in each cell lines was 
divided by the Int value of GAPDH correspondingly, and the expression analysis figures were 
made based on these data with standard error by Excel 2010. 
3.4 xCelligence 
3.4.1 Principle of xCelligence 
In our study, cell function test experiments were all performed with the xCelligence system, 
which is an electronic real-time cell-sensing assay (RTCA), providing real-time, continuous 
sensitive monitoring of cellular responses [105]. The RTCA instrument is composed of a 
RTCA impedance analyzer, a computer with RTCA software for controlling the system 
operation, electronic microwell plates and the RTCA station which is placed inside the tissue 
culture incubator. The microwell plates such as E-Plate and CIM-Plate whose bottoms are 80% 
covered with microelectrodes that measure the impedance differences within an electrical 
circuit. These differences are converted into cell index (CI), a value that may be influenced by 
several parameters, such as cell number, cell size, cell-substrate, or cell–cell attachment which 
also directly influenced by cell attachment, spreading, and/or cell proliferation. Featuring a 
dual-plate (DP) format, the instrument measures impedance-based signals in both cellular and 
cell invasion/migration (CIM) assays – without the use of exogenous labels. With outstanding 
application flexibility, the RTCA DP Instrument supports multiple users performing short-
term and long-term experiments. 
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3.4.2 Cell Proliferation analysis by xCelligence 
For cell proliferation analysis, the E-Plate was used in this xCelligence system. And the cell 
proliferation assay were performed twice, at the first time RTCA station was placed in a 
normal incubator (37°C, CO2 5%, O2 21%), at the second time RTCA station was placed in a 
low oxygen incubator (37°C, CO2 5%, O2 5%). 
100 µl of cell culture medium was added to each well for the impedance background 
measurement. The cells of six NZM cell lines were harvest as before, and were added as 
Table 21. After adding the cells, the final volume was 200 µL. The E-Plates were monitored 
on the RTCA system at 200 sweeps×30 minutes for up to 100 hours. Table 21: The layout of 
E-Plate for cell proliferation 
A1: NZM9  (20000 cells) A2: NZM9  (20000 cells) 
B1: NZM17  (20000 cells) B2: NZM17  (20000 cells) 
C1: NZM22  (20000 cells) C2: NZM22  (20000 cells) 
D1: NZM40  (20000 cells) D2: NZM40  (20000 cells) 
E1: NZM59  (20000 cells) E2: NZM59  (20000 cells) 
F1: NZM86  (20000 cells) F2: NZM86  (20000 cells) 
G1: Control (only medium) G2: Control (only medium) 
H1: Control (only medium) H2: Control (only medium) 
 
3.4.3 Cell Migration analysis by xCelligence 
The ability of cell migration was also monitored in real-time with the xCelligence system 
(CIM-Plates), also both with the normal incubator (37°C, CO2 5%, O2 21%) and a low 
oxygen incubator (37°C, CO2 5%, O2 5%).The CIM-Plate is composed of two chambers, 
only the bottom of lower chamber has microelectrodes. In the migration assay 5% Fetal 
Bovine Serum (FBS) in the lower chamber was as attractant. The lower chamber was added 
160 µl medium (Table 22), and the upper chamber was added 30 µl Serum-free medium. 
After assembling the CIM-Plate, it was performed for background measurement. The cells of 
the six NZM cell lines were washed and trypsinized. TNS solution was added at a 1:1 ratio to 
stop trypsinization. After centrifuging as before, cells were resuspended in FBS-free medium 
and then seeded in the upper chamber Table 22. The CIM-plates was left in an incubator for 
30 minutes to allow cell attachment. The impedance value of each well was automatically 
monitored by the xCelligence system at 100 sweeps×15 minutes for 25h and expressed as a 
CI value. 
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Table 22: The layout of CIM-Plate for cell migration 
A1: upper-NZM9 (20000 cells) in FBS free medium,  
lower-5%FBS medium 
A2: upper-NZM9 (20000 cells) in FBS free medium,  
lower-5%FBS medium 
B1: upper-NZM17(20000 cells) in FBS free medium,  
lower-5%FBS medium 
B2: upper-NZM17(20000 cells) in FBS free medium,  
lower-5%FBS medium 
C1: upper-NZM22(20000 cells) in FBS free medium,  
lower-5%FBS medium 
C2: upper-NZM22(20000 cells) in FBS free medium,  
lower-5%FBS medium 
D1: upper-NZM40(20000 cells) in FBS free medium,  
lower-5%FBS medium 
D2: upper-NZM40(20000 cells) in FBS free medium,  
lower-5%FBS medium 
E1: upper-NZM59(20000 cells) in FBS free medium,  
lower-5%FBS medium 
E2: upper-NZM59(20000 cells) in FBS free medium,  
lower-5%FBS medium 
F1: upper-NZM86(20000 cells) in FBS free medium,  
lower-5%FBS medium 
F2: upper-NZM86(20000 cells) in FBS free medium,  
lower-5%FBS medium 
G1: upper-FBS free medium, low-FBS medium G2: upper-FBS free medium, low-FBS medium 
H1: upper- FBS free medium, low-FBS medium H2: upper- FBS free medium, low-FBS medium 
 
3.4.4 Cell Invasion analysis by xCelligence 
Detection of cell invasion was performed with the xCelligence system RTCA DP Instrument 
and CIM-Plate using Matrigel basement membrane matrix. Matrigel is a meshwork of 
extracellular matrix (ECM) proteins and growth factors which mimics the basement 
membrane underlying epithelial cells and has been broadly used for assessing cell invasion, 
especially cancer cell invasion in vitro. Firstly the upper chamber of CIM-Plate was coated 
with 20 µl of Matrigel which was diluted at 1:20 with serum free medium and left in 37°C 
incubator for 4 hours. Each well in the lower chamber was filled with 160 µl as Table 23. 
After 1 hour 37°C incubation, the CIM-Plate 16 was performed a background measurement.  
Table 23: Arrangement of Matrigel and medium in CIM-Plate 16 for cell invasion 
A1: upper-Matrigel 1:20 pre-coated,  
lower-160 µl of 5%  FBS medium 
A2: upper-Matrigel 1:20 pre-coated,  
lower-160 µl of 5%  FBS medium 
B1: upper-Matrigel 1:20 pre-coated,  
lower-160 µl of 5%  FBS medium 
B2: upper-Matrigel 1:20 pre-coated,  
lower-160 µl of 5%  FBS medium 
C1: upper-Matrigel 1:20 pre-coated,  
lower-160 µl of 5%  FBS medium 
C2: upper-Matrigel 1:20 pre-coated,  
lower-160 µl of 5%  FBS medium 
D1: upper-Matrigel 1:20 pre-coated,  
lower-160 µl of 5%  FBS medium 
D2: upper-Matrigel 1:20 pre-coated,  
lower-160 µl of 5%  FBS medium 
E1: upper-Matrigel 1:20 pre-coated,  
lower-160 µl of 5%  FBS medium 
E2: upper-Matrigel 1:20 pre-coated,  
lower-160 µl of 5%  FBS medium 
F1: upper-Matrigel 1:20 pre-coated,  
lower-160 µl of 5%  FBS medium 
F2: : upper-Matrigel 1:20 pre-coated,  
lower-160 µl of 5%  FBS medium 
G1: upper-Uncoated,  
lower-160 µl of 5%  FBS medium 
G2: upper-Uncoated,  
lower-160 µl of 5%  FBS medium 
H1: upper-Uncoated,  
lower-160 µl of  FBS free medium 
H2: upper-Uncoated,  
lower-160 µl of  FBS free medium 
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Cells of the six NZM cell lines were harvest as cell migration part, and seeded as Table 
23.The CIM-plates was left in an incubator for 30 minutes to allow cell attachment. The 
impedance value of each well was automatically monitored by the xCelligence system at 100 
sweeps×15 minutes for 25h and expressed as a CI value. 
 
3.5 CRISPR 
3.5.1 Principle of CRISPR 
Clustered regularly interspaced palindromic repeats (CRISPR) is a microbial nuclease system 
which consists of the CRISPR-associated (Cas) genes and noncoding RNA elements, can 
program the specificity of nucleic acid cleavage. Type II CRISPR/Cas9 uses a CRISPR RNA 
(crRNA) and a trans-activating RNA (tracrRNA) to guide the Cas9 DNA endonuclease to 
induce sequence-specific double-strand breaks (DSBs) [106, 107]. CRISPR/Cas9 mediated 
DSBs of the target DNA is recognized and repaired by the cellular DNA repair machinery via 
non-homologous end joining (NHEJ) typically resulting in short nucleotide deletions or 
insertions (indels), which disrupt the target gene [108] or homology-directed repair (HDR), 
which can be exploited to precisely edit genomic sequence or insert exogenous DNA [109]. 
 
 
 
Figure 4: DSBs can be repaired via NHEJ or HDR. In the error-prone NHEJ pathway, it can 
result in random indel mutations at the site of junction. Indel mutations occurring within the 
coding region of a gene can result in frameshifts and the creation of a premature stop codon, 
resulting in gene knockout. Alternatively, a repair template in the form of a plasmid or ssODN 
can be supplied to leverage the HDR pathway, which allows high fidelity and precise editing. 
Adapted from Reference [110]. 
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3.5.2 Target selection of Human Axl  
Human Axl genomic DNA sequence was inputed in an online CRISPR Design Tool (NCBI), 
the 20-bp sequence directly upstream of any 5′-NGG was identified. According to NCBI 
Gene, there may be a human Axl splice form that used alternative 5' exons. One place to make 
gRNA would be to the first COMMON exon, which is exon 7, and another place to make 
gRNA would be to kinase domain. In this study, Hs Axl exon 7 was chosen as the target 
sequence. And according to the target sequence, two pairs of oligos were ordered from IDT 
Company. 
 
3.5.3 Making of CRISPR construct 
In this part, two pairs of oligos were resuspended to a final concentration of 100 μM. The 
mixture was made (Table 24) for phosphorylating and annealing the oligos. The mixture was 
placed in a thermocycler by using the following parameters: 37 °C for 30 min; 95 °C for 5 
min; ramp down to 25 °C at 5 °C min–1. Then the annealed oligo was diluted 1:250 by adding 
1 μl of oligo to 249 μl of room temperature ddH2O. 
Table 24: Reaction solutions for making CRISPR construct. 
Component Amount (μl) 
Oligo 1: Hs Axl for (100 μM) 1 
Oligo 2: Hs Axl rev (100 μM) 1 
T4 ligation buffer, 10× 1 
T4 PNK 0.5 
ddH2O 6.5 
Total 10 
 
When the oligos was phosphorylated and annealed, they were cloned into pSpCas9n(BB)-2A-
GFP(PX461) which contains marker GFP to aid the selection of transfected cells.A ligation 
reaction was set up as described below Table 25. The ligation reaction was then incubated in 
a thermocycler: 37oC 5 min, 23oC 5 min, cycle the previous two steps for 6 cycles (total run 
time 1h), 4 
o
C hold until ready to proceed. 
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Figure 5: Gene map of pSpCas9n(BB)-2A-GFP(pX461). It carries a GFP marker for 
identification of transfected cells. 
Table 25: Reaction solutions for ligation reaction 
Component Amount (μl) 
pSpCas9(BB), 100 ng (13.25ng/µl) 7.5 
phosphorylated and annealed oligo duplex 
from above (1:250 dilution) 
2 
FastDigest Buffer, 10× 2 
DTT (10mM to a final concentration of 
1mM) 
1 
ATP (10mM to a final concentration of 
1mM) 
1 
FastDigest BbsI 1 
T7 DNA ligase 0.5 
ddH2O 5 
Total 20 
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3.5.4 Transform the plasmid into NEB 10-beta competent E.coli (C3019). 
According to the protocol supplied with the cells, cells were thawed on ice and 50µl of cells 
was mixed and transferred into a transformation tube. Then 5 μl of CRISPR construct was 
added into the transformation tube, the mixture was incubated on ice for 30 min, heated-shock 
at 42 °C for 30 s, returned immediately to ice for 5 min. 950 µl of room temperature SOC 
medium was added into the mixture, which was then placed at 37°C for 60 min. After 
performing several 10-fold serial dilutions (1:10, 1:100, and 1:1000) in SOC, 100 µl of each 
dilution were spread onto the pre-warmed selection plates containing ampicillin 100 μg/ml. 
The plates were incubated at 37°C for 24 hours. 
3.5.5 DNA isolation for sequencing 
From each plate, 2 colonies were picked to check for correct insertion of gRNA. Each single 
colony was inoculated into a 10 ml LB medium with 100 µg/ml ampicillin by sterile pipette 
tips. Then it was cultured and shaken at 37 °C overnight. The isolation of the plasmid DNA 
from cultures was performed using a QIAprep spin miniprep kit according to the 
manufacturer’s instructions. 
10 ml bacterial overnight culture was centrifuged at 10,000 rpm for 3 min at room 
temperature, and then the cells were resuspended in 250 µl P1 buffer and transferred into 
Eppendorf tubes. After adding 250 µl P2 buffer, tubes were mixed thoroughly, then the same 
as 350 µl N3 buffer. Tubes were centrifuged at 13,000 rpm for 10 min, and the supernatant 
was transferred into QIAprep spin column for 45s centrifuging. After adding 500 µl buffer PB, 
they were centrifuged as before, so did 750 µl buffer PE. Finally residual washing buffer was 
removed by 1 min centrifuging, and DNA was eluted by adding 50 µl buffer EB which was 
measured by Nanodrop.  
Table 26: A mixture reaction was made for sequencing. 
Component Amount  
BigDye v3.1 1 μl 
Sequence buffer, 5x 2 μl 
DK157 primer, 10µM 0.5 
DNA templat  200ng 
MilliQ - 
Total 10 µl 
 
Table 27: The program for mixture reaction in a thermocycler 
Temperature  Time Cycles 
96 °C 1 min 1 
96 °C 10 sec 25 
50 °C 5 sec 
60 °C 4 min 
4 °C hold - 
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After got the concentration of DNA from Nanodrop, the volum of 200 ng DNA in each 
sample was calculated. Then the materials in Table 26 was mixed and followed by a reaction 
as Table 27 in a thermocyler. After reaction, DNA was sent for sequencing, which was 
performed by Sekvenseringslaboratoriet (under Seksjon for laboratoriediagnostikk ved Senter 
for medisinsk genetikk og molekylærmedisin, Haukeland Universitetssykehus). 
3.5.6 DNA isolation for transfection 
This part was similar with DNA isolation with QIAprep spin miniprep kit described above, 
which was performed using a QIAGEN Plasmid Midi Kit according to the manufacturer’s 
instructions. This protocol was designed for preparation of up to 100 µg of high- or low-copy 
plasmid or cosmid DNA. The colony which has right sequence results was picked and 
inoculated into a 150 ml LB medium with 100 µg/ml ampicillin by sterile pipette tips. Then it 
was cultured and shaken at 37 °C overnight. 
The bacterial cells were harvested by centrifugation at 6000 ×g for 15 min at 4 °C, and then 
resuspended in 4 ml buffer P1. After adding 4 ml buffer P2, it was mixed thoroughly and 
incubated at room temperature for 5 min. 4 ml buffer P3 was added and mixed, incubated on 
ice for 15 min. Tubes were centrifuged at 20,000 rpm for 30 min at 4°C, and the supernatant 
was transferred and continued centrifuging at 20,000 rpm for 15 min at 4°C. A QIAGEN-tip 
100 was equilibrated by adding 4 ml buffer QBT, the column was allowed to empty by 
gravity flow, it was repeated with the supernatant from centrifugation. The QIAGEN-tip was 
washed twice by 10 ml buffer QC. Then the DNA was eluted by 5 ml buffer QF which was 
also measured by Nanodrop. 
3.5.7 Transfection 
Electroporation is one of the most efficient non-viral methods for transferring exogenous 
DNA into mammalian cells. In this part, we used Neon transfection system to transfect the 
DNA described above to our NZM17 cells. The Neon system employs specialized 
consumable pipette tips containing gold-plated electrodes as electroporation chamber, and has 
three electric parameters including Pulse voltage, Pulse width and Pulse number, In general, 
the use of such a capillary electroporation system (which is often called a microporation 
device) has important advantages compared with conventional cuvette-based electroporation 
chambers including high efficiency, flexibility, simplicity, versatility and easy to use protocol.  
Microporation was done using the Neon™ Transfection System as follows: NZM17 cells 
were split when they reached 70%-90% confluent, the next day medium was changed with 
medium without antibiotics. On the third day, NZM17 cells were washed with PBS (without 
Ca
2+
 and Mg
2+
) and trypsinized for exactly 3 min at 37 °C, and the detached cells were 
counted and centrifuged in non-antibiotics medium at 400×g for 5 min. The cell pellet was 
resuspended, and 2.5 × 10
5
 cells were transferred to a tube and again centrifuged. We added 
25 µg CRISPR DNA plus 250 µl R-buffer to the pellet (0.5-2 µg DNA/10µl mixture/well). 10 
µl of the volume of this mixture was aspirated into the Gold-Tip of the MicroPorator Pipette 
of the Neon™ Transfection System. After microporation as followed Optimization (Table 28), 
the 10 µl inside the Gold-Tip was immediately released into a 24-well plate already filled 
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with culture medium without antibiotics—this step was repeated with the other 230 µl of the 
above-mentioned mixture. Then the 24-well plates were placed into the low oxygen incubator 
(37°C, 5%CO2, 5%O2). Culture medium with antibiotics was changed 24 hours later, and the 
plate was ready for Fluorescent picturing. After finding the best transfection condition, the 
transfection was repeated under the best condition setting.  
Table 28: Optimization form 
Sample Well no. Pulse voltage Pulse width Pulse no. 
1 A1 0 (control) 0 (control) 0 (control) 
2 A2 1400 20 1 
3 A3 1500 20 1 
4 A4 1600 20 1 
5 A5 1700 20 1 
6 A6 1100 30 1 
7 B1 1200 30 1 
8 B2 1300 30 1 
9 B3 1400 30 1 
10 B4 1000 40 1 
11 B5 1100 40 1 
12 B6 1200 40 1 
13 C1 1100 20 2 
14 C2 1200 20 2 
15 C3 1300 20 2 
16 C4 1400 20 2 
17 C5 850 30 2 
18 C6 950 30 2 
19 D1 1050 30 2 
20 D2 1150 30 2 
21 D3 1300 10 3 
22 D4 1400 10 3 
23 D5 1500 10 3 
24 D6 1600 10 3 
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3.5.8 Brightfield and Fluorescence microscopy 
After transfection, the NZM17 cells cultured in 24-well plates were monitored daily using an 
Olympus CKX41 inverted fluorescence microscope connected to a power supply unit U-
RFLT50. The Olympus CKX41 has blue (Fluorescein isothiocyanate, FITC) filters and is 
suitable for regular cell observation including GFP and other fluorescence applications. Post-
transfection fluorescence images of NZM17 cells were acquired by Nikon TE2000 system. 
The Nikon TE2000 system was composed of TE2000 inverted microscope, mercury/UV lamp, 
NIS-Elements software (NIS-Elements AR 4.20.00), TE2000 control pad, color camera, and 
so on. After the system was switched on, the post-transfection NZM17 cells in a well of a 24-
well plate were focused in the TE2000 inverted microscope. A camera control unit of DS-
U2/L2 USB was selected in NIS-Elements AR 4.20.00 software, and the correction collar in 
the objectives was adjusted for cover slip thickness between 0 and 2mm. In the lambda 
window, the optical configurations of brightfield and FITC were selected. Then the pictures 
were taken separately under brightfield and FITC filters. After photographing, three kinds of 
cells pictures can be acquired including a mono picture, a FITC picture and a coincide picture. 
The fluorescence microscopy was repeated with each well of every 24-well plates with post-
transfection NZM17 cells. 
3.6 Flow cytometry 
3.6.1 Principle of flow cytometry 
Flow cytometry is defined as the simultaneous measurement of multiple physical 
characteristics of a single cell as the cell flows in suspension through a measuring device. It is 
a subset of the field of cytometry based on the use of specialized instruments. In flow 
cytometry, the measurements are made as the cells or particles pass through the measuring 
apparatus. A flow cytometer includes a laser beam used as the light source to excite a 
fluorescent tag bound to the cells in the specimen; an argon laser which produces light; a cell 
sorter, or flow sorter, which uses electrical and/or mechanical means to divert and collect cells 
(or other small particles) with measured characteristics that fall within a user-selected range of 
values and so on. 
Flow cytometry measures multiple characteristics of individual particles flowing in single file 
in a stream of fluid. Light scattering at different angles can distinguish differences in size and 
internal complexity, whereas light emitted from fluorescently labeled antibodies can identify a 
wide array of cell surface and cytoplasmic antigens. This approach makes flow cytometry a 
powerful tool for detailed analysis of complex populations in a short period of time [111]. 
3.6.2 Protocol 
In this part, we used flow cytometry to check the expression of Axl after CRISPR knocking 
out. In the first time, NZM17 cells which were cultured 72 hours post transfection were 
collected by washing with PBS, trypsinization and centrifugation at 1200 rpm/5 min. Then the 
cells were resuspended in PBS, counted and the concentration was adjusted to 10
6
cells/ml. 2 
ml sample and negative control of NZM17 cells without transfection were directly sent for 
sorting GFP positive cells by flow cytometor FACS Aria (performed by Marianne Enger). 
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After sorting, cells were cultured in a T75 flask as before. When cells were enriched, the post 
sorting NZM17 cells   were collected by washing with PBS, trypsinization and centrifugation 
at 1200 rpm/5 min. Then the cells were resuspended in 100 µl formaldehyde mixed with 900 
µl PBS (final concentration 4%) and fixated for 10 min at 37ºC. After 1 more min on ice, the 
cells were resuspended in PBS and the concentration was adjusted to 10
6
cells/ml. 
3 Eppendorf tubes were prepared and labelled, and each was added 1 x 106cells. After adding 
1 ml PBS-1% BSA to each tube, the tubes were centrifuge at 700×g for 5 min. The most of 
supernatant was gently aspirated, and the cells were resuspend by gently tapping the tube. 100 
µl of diluted anti-Axl in cold PBS-1%BSA was added to the third tube (final concentration is 
2.5 µg/106 cells), the other two tubes were added only 100 µl of PBS-1%BSA, and all of the 
three tubes were incubated for 30 min at room temperature in tublewheel. After incubation all 
the tubes were washed with 1 ml PBS-1%BSA and centrifuged above twice. 100 µl of diluted 
secondary antibody Alexa Fluor® 647 (final concentration 10µg/ml) was added to the second 
and third tube; 100 µl of PBS-1% BSA was added to the first tube. Like above, these were 
mixed well and kept in tublewheel at room temperature for 20 minutes. Then it was also 
followed by washing with PBS-0.5% BSA and centrifuging twice. Finally, cells were 
resuspended in 250 µl PBS-0.5% BSA. Data was acquired by using a flow cytometer Acurri 
C6, and analyzed by cFlow Sampler Analysis software. 
In the second time, NZM17 cells which were cultured 24hour, 48hours, and 72 hours after 
transfection were tested Axl and GFP expression by flow cytometer Acurri C6 as above 
without sorting. 
 
3.7 Statistical analysis 
 
In this study, all the statistics analysis was performed by Excel 2010. The data in expression 
experiments was first calculated for ratio by dividing reference contrast, and then expressed 
with mean ± SD ( x̅±s ). Column figures were based on the mean value and showed error bars 
with standard error. In cell function analysis, the data in figures were also based on mean 
value of two replicates and showed with SD.   
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Results 
4.1 Expression analysis of NZM cell lines 
4.1.1 Morphology of NZM cell lines 
We received six NZM cell lines from New Zealand; they were thawed and cultured in a low 
oxygen incubator (5% O2, 5% CO2, 37°C). In common practice for in vitro cell culture, cells 
were often cultured in normal incubators (5% CO2, 37°C) where the O2 tension corresponds 
to atmospheric levels (21% O2) [112]. However, the endogenous physiological O2 tension 
found in tissues was in the range of 2–5% [113, 114], in order to mimic physiologically low 
oxygen levels in tumors, the six NZM cell lines were cultured in the low oxygen incubator (5% 
O2, 5% CO2, 37°C). The morphology of the cell lines varied, with some being more 
epithelial-like and others more fibroblastic-like (Figure 6). When cells reached 70-90% 
confluence, they were 1:4 passaged. However, the requiring passing time was different: 
NZM17, NZM40, and NZM86 required passaging 2 times a week, while NZM9, NZM22 and 
NZM59 required passaging 1 time a week.  
NZM 9                                            NZM17                                               NZM22 
   
NZM 40                                           NZM59                                             NZM86 
   
Figure 6: Images of the six NZM cell lines (100× under microscope of Nikon ECLIPSE 
TS100 ). The morphology of the cell lines varies: NZM9 was more fibroblastic-like and 
others more epithelial -like. 
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4.1.2 Expression of Axl in the NZM cell lines.  
According to Kim et al., all the six cell lines expressed high level of Axl [115]. In order to 
validate the Axl expression level in our six NZM cell lines, we measured the Axl expression 
both in gene level by RT-PCR and protein level by Western blot. The data was shown in 
Figure 7 and Figure 8. In RT-PCR, we used two reference genes, human beta-actin and 
human 18s RNA, besides we also evaluated at two concentrations:1:10 and 1:100. According 
to the Crossing Point (CP) value of the six NZM cell lines, we used Axl CP value to divide 
CP value of reference gene, and organized the data shown in Figure 7. From Figure 7, we 
can find that when human beta-actin is used as reference gene, the difference expression level 
of Axl was comparably obvious. From the CP definition, a higher of CP value means the 
lower expression. From this analysis, NZM17 had the highest expression of Axl, besides 
NZM40 and NZM86 expressed relatively lower Axl.  
 
  
Figure 7: CP value of Axl as ratios to two reference genes including human beta-actin and 
human 18s rRNA at two concentration levels (1:10, 1:100).  
 
 
To further check Axl expression among the six NZM cell lines at protein level, and also to 
validate the data from Kim [115], we did Western blot to analyze the Axl and phospho-Axl 
expression among them. The data was shown in Figure 8A, we also quantificed the Western 
blot results, shown in Figure 8B. From both A and B, we can find that NZM17 has the 
highest expression of Axl, corresponding with the RT-PCR results, while the other cell lines 
have quite low expression or even do not express Axl protein. Our results differ with the data 
from Kim et al. [115]. According to Kim et al., all of the six NZM cell lines have similar high 
signal of Axl, but in our data (Figure 8A) only NZM17 has quite strong signal, NZM9 and 
NZM22 have relatively high signals, while the other three do not show clear bands; and 
according to Kim et al., NZM9, NZM17 and NZM86 all have relatively high ratios as to  
reference β-actin, but in Figure 8B only NZM17 has obviously high ratio as to reference 
GAPDH compared with others.  
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A                                                                            
Axl                
GAPDH        
                       NZM9   NZM17    NZM22   NZM40  NZM59   NZM86 
B 
 
 
Figure 8: Western results of Axl in the six NZM cell lines with GAPDH as reference. A 
shows the bands of Axl and GAPDH of the six NZM cell lines, in which NZM17 has the 
strongest signal band in Axl expression; B shows the quantification results of Western blot.  
                                                     
We also analyzed the level of phospho-Axl (Y702) to measure Axl activation levels among 
the six NZM cell lines. The data was shown in Figure 9. The quantitation (Figure 9B), shows 
that NZM17 had the highest level of phospho-Axl. 
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Figure 9: Western results of pAxl (Y702) in the six NZM cell lines with GAPDH as reference. 
A shows the bands of pAxl and GAPDH of the six NZM cell lines, in which NZM17 has the 
strongest signal band in pAxl expression; B shows the quantification results of western blot. 
 
 
4.1.3 Expression of Akt3 in the six NZM cell lines. 
 
To test the hypothesis model of Axl affect melanoma metastasis via activation of Akt3, Akt3 
expression analysis perfomed at transcript level by RT-PCR and protein level by Western blot. 
First, we used RT-PCR to find whether all the six cell lines express Akt3, the data was shown 
in Figure 10. Similar with Axl expression of RT-PCR, we also checked the Akt3 expression 
with two reference gene human beta-actin and human 18s RNA in two concentration levels 
1:10 and 1:100. From Figure 10 we can see that even using different reference genes and 
concentrations, we got similar CP value trends. NZM40 had the highest CP value suggesting 
the lowest Akt3 mRNA expression. Also in Figure 10, it showed NZM17, NZM22 and 
NZM86 had relatively higher CP value indicating a relatively low Akt3 expression. NZM9 
and NZM59 had higher expression of Akt3. 
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Figure 10:  CP value of Akt3 as ratios to two reference genes including human beta-actin and 
human 18s rRNA at two concentration levels (1:10, 1:100). 
We also checked the Akt3 protein expression levels by Western blot. The data is shown in 
Figure 11. Different with the gene expression results from RT-PCR (Figure 10), we found 
that NZM86 has the highest expression of Akt3 (Figure 11). Besides we found that NZM9 
has the lowest expression of Akt3 (Figure 11B), which was opposite to the results in RT-PCR 
(Figure 10, in which NZM9 has the lowest CP value with the highest expression gene level of 
Akt3).  
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Figure 11: Western blot results of Akt3 in the six NZM cell lines with GAPDH as reference. 
A shows the bands of Akt3 and GAPDH of the six NZM cell lines, in which NZM86 has the 
strongest signal band in Akt3 expression; B shows the quantification results of Western blot. 
 
 
4.2 Cell function analysis of the six NZM cell lines by xCelligence 
system 
4.2.1 Proliferation 
We tested the proliferation of our six NZM cell lines by xCelligence system, we did it twice 
separately in a normal incubator (21% O2, 5% CO2, 37ºC) and a low oxygen incubator (5% 
O2, 5% CO2, 37ºC).The figure of growth from xCelligence system was shown in Figure 12A 
(21% O2) and B (5% O2). Firstly we found cells grew differently when the oxygen 
concentration was different. Figure 12A showed that NZM17 which was an Axl-Akt3 co-
expression cell line had the highest CI value, but it needed the longest time to arrive stable. 
Besides NZM40 and NZM86 had comparatively higher proliferation level while NZM9, 
NZM22 and NZM59 have lower level. Figure 12B showed similar comparison results among 
the six cell lines. However CI value of NZM17 and NZM22 showed a clear reduction around 
40 hours later before they arrived stable. 
 
To study the difference of cell proliferation between the two incubators with different oxygen 
concentration, we compared the CI value from two incubators at three time points including 
24, 48 and 100 hours. The data was shown in Figure 12C, D, and E. From Figure 12C we 
can find that the Axl-Akt3 co-expression NZM17 grew faster in the low oxygen incubator 
than the normal incubator at 24 hours, but the growth rate of NZM17 in low oxygen incubator 
reduced over time (Figure 12D). From Figure 12E we found the CI value of low oxygen 
incubator became lower than normal incubator. Besides we can also find that NZM40 grows 
faster in normal incubator and NZM59 grew faster in low oxygen incubator.    
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Figure 12: The different proliferation level of the six NZM cell lines tested by xCelligence 
system. A: Proliferation tested by xCelligence in a normal incubator (21% O2. 5% CO2, 37°C); 
B: Proliferation tested by xCelligence in a low oxygen incubator (5% O2. 5% CO2, 37°C); C: 
CI value comparison at 24 hour; D: CI value comparison at 48 hour; E: CI value comparison 
at 100 hour.  
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4.2.2 Migration 
Similar to proliferation experiment, the migration experiment was also performed by 
xCelligence system separately in two oxygen concentration incubators (Figure 13).  From 
Figure 13A and B, we found that all the CI trend lines of the six NZM cell lines were quite 
similar; the only difference was in NZM40, but the Standard deviation (SD) of it was quite 
bigger in both Figures 13A and B, so we cannot prove the weather the migration level was 
different in different oxygen concentration incubators. We also compared the CI value from 
two incubators (Figure 13C), it was shown that there was no big differences expect NZM40, 
which was coincide the results from Figure 13A and B. The Axl-Akt3 co-expression cell line 
NZM17 also showed much higher cell migration compared with other cell lines.  
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Figure 13: The migration level of the six NZM cell lines tested by xCelligence system. A: 
Migration tested by xCelligence in a normal incubator (21% O2. 5% CO2, 37°C); B: 
Migration tested by xCelligence in a low oxygen incubator (5% O2. 5% CO2, 37°C); C: CI 
value comparison at 24 hour. 
4.2.3 Invasion 
Figure 14 showed the data of Cell Invasion experiment by xCelligence system performed in 
the two kinds of incubator. It was obviously different oxygen concentration had an important 
influence in cell invasion ability. In Figure 14A, the CI value of NZM9, 17 and 59 improved 
a lot after 20 hours, while the other three cell lines still kept relatively lower and stable CI 
value. In Figure 14B, NZM40 which had the highest CP value of Akt3 (Figure 10) showed 
the highest invasion level; and NZM86 which had the highest Akt3 expression in protein level 
(Figure 11A and B) had the lowest CI value of invasion. Besides, the Axl-Akt3 co-expression 
cell line NZM17 showed relatively higher invasion level both in normal incubator and low 
oxygen incubator. According to the results of comparison in Figure 14C, it was obvious that 
most NZM cell lines showed higher invasion ability in normal incubator than the low oxygen 
incubator expect NZM22.   
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Figure 14: The Invasion level of the six NZM cell lines tested by xCelligence system. A: 
Invasion tested by xCelligence in a normal incubator (21% O2. 5% CO2, 37°C); B: Invasion 
tested by xCelligence in a low oxygen incubator (5% O2. 5% CO2, 37°C); C: CI value 
comparison at 24 hour. 
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4.3 Axl knocking out by CRISPR 
CRISPR is a microbial nuclease system which consists of the CRISPR-associated (Cas) genes 
and noncoding RNA elements, can program the specificity of nucleic acid cleavage. 
CRISPR/Cas9 mediated DSBs of the target DNA is recognized and repaired by the cellular 
DNA repair machinery via NHEJ which can disrupt the target gene [108] or HDR, which can 
be exploited to precisely edit genomic sequence or insert exogenous DNA [109]. Therefore, 
we may permanently knock out Axl by using this system.  
4.3.1 Target selection of Human Axl  
The target selection of Human Axl was done by Dr. David Micklem. Human Axl genomic 
DNA sequence was inputted in an online CRISPR Design Tool (NCBI), the 20-bp sequence 
directly upstream of any 5′-NGG was identified. According to NCBI Gene (Figure 15), Hs 
Axl exon 7 was chosen as the target sequence, and two pairs of oligos were ordered 
accordingly. The oligos was phosphorylated, annealed, and cloned into pSpCas9n(BB)-2A-
GFP(pX461) which contains marker GFP to aid the selection of transfected cells. Then the 
CRISPR construct were enriched by NEB 10-beta competent E.coli and clonies were formed 
in selection plates. 
 
Hs Axl Exon 7: 
Top scoring pair from MIT (no off targets) is: 
 Guide A 87 
 quality  high 
 cuts after position 166 in query 
 sequence GCTGCCTAGCCGAAGCTGATggg 
 # offtargets 92 
 # genic offtargets 21 
     
     Guide B 97 
 Quality high 
 cuts after position 217 in query 
 sequence CACCCCTTATCACATCCGCGtgg 
 # offtargets 35 
 # genic offtargets 4 
 
Oligos to order for Hs Axl Exon7: 
  
 GuideAfor caccGCTGCCTAGCCGAAGCTGAT 
 GuideArev   aaacATCAGCTTCGGCTAGGCAGC 
 
 GuideBfor caccgCACCCCTTATCACATCCGCG 
GuideBrev aaacCGCGGATGTGATAAGGGGTGc 
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Figure 15: Design and order oligos. For Axl, exon 7 was chosen to make gRNA. According 
to the top scoring, two guide sequences were chosen and two pairs of oligos were ordered. 
(with Dr. David Micklem). 
4.3.2 Sequence of CRISPR constract 
After the CRISPR construct prepared, we sequenced 6 clones from different dilution selection 
plates. The expected insertion of gRNAs sequence was detected  in 5 clones and one of the 
clones did not show the right sequence (Figure 16). Figure 16A and B showed that the 
sequence Guide A forward oligo (highlighted in red box) was successfully cloned into the 
plasmid; Figure 16D, E and F showed that the sequence of Guide B forward oligo 
(highlighted in red box) were seamlessly cloned into the plasmid; in Figure 16C, we did not 
find the right insertion. 
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Figure 16: Sequence of the guide sequence oligos cloned into the plasmid. A and B show 
Guide A forward oligo (highlighted in red box) was successfully cloned into the plasmid; D, 
E and F show that the sequence of Guide B forward oligo (highlighted in red box) were 
seamlessly cloned into the plasmid; C did not show the right insertion. 
 
4.3.3 Transfection 
The Neon electroporation transfection system was used for transfecting the CRISPR plasmid 
into NZM17 cells which had the highest Axl expression (Figure 9). Electroporation was 
mainly dependent on the combination of three electric parameters such as the electric field, 
pulse width, and pulse number. Because there were no available optimized electroporation 
parameters for our cell type, we first did a 24-well optimization. 24-hours later images were 
acquired from each well of the plate using a Nikon TE2000 fluorescence microscope. The 
images were taken separately under brightfield and FITC filters. GFP expression from the 
CRISPR plasmid was used to show successfully transfected cells. From the images we 
determined that the best electric parameters for NZM17 were: Pulse voltage--850; Pulse 
width--30; Pulse no.—2. 
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Based on the optimized parameters of NZM17, we repeated the transfection, and the 
fluorescence microscopy images were acquired after 48 hours (Figure 17). GFP-expressing 
cells were apparent in the transfected cultures.  
 
A                                             B                                            C 
   
Figure 17: Images of post-transfection NZM17 cells taken by Nikon TE2000 system. A: The 
monoculture bright field image; B:  Fluorescence microscopy image in FITC channel; C: A 
overlay of A and B. In the pictures of B and C, cells with GFP-expressing (green) cells 
showed successful transfection by electroporation. 
4.4 Analysis of Axl CRISP-knocking out by flow cytometry 
4.4.1 Axl knocking out analysis by flow cytometry after GFP sorting. 
We analysed the CRISPR plasmid transiently transfected NZM17 cells by flow cytometry to 
measure Axl and GFP levels and enable enrichment by cell sorting. When the cells in the well 
reached confluence, we transferred these cells into a small flask in order to expand for sorting. 
However, the cells grew so fast that the next day, no GFP-expressing cells could be found by 
fluorescence microscopy. The second time 72 hours after transfection cells grew confluent in 
the 24-well plate and we directly harvested the cells (around 10
6
 cells) and sorted for GFP 
positive cells (around 7000 cells) by flow cytometor FACS Aria (performed by Marianne 
Enger). Then the GFP positive cells were cultured and Axl levels were measured by flow 
cytometry, the data was shown in Figure 18. From Figure 18C we can find that there was 
99.6% of cells still expressed Axl, meaning only 0.4% cells might be Axl knocking out cells. 
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A                                             B                                           C 
    
Figure 18: Axl expression by flow cytometry after CRISPR transfection. A: Looking for the 
right active cells. B: Making a gate of Axl positive/negative expression. C: 99.6% of cells still 
expressed Axl, indicating only 0.4% cells might be Axl knocking out cells.  
4.4.2 Time course analysis of Axl knock out by flow cytometry 
To further analyzing the Axl expression of post-CRISPR Axl knock-out plasmid transfection, 
we harvested the cells from the plate separately at 24 hours, 48 hours and 72 hours after 
transfection, and analyzed Axl and GPF expression again by flow cytometry. The data is 
shown in Figure 19. From the results we found most cells still expressed Axl (Figure 19Aa, 
Ba and Ca); there were some cells transfected with the plasmid and expressed GFP signals 
(Figure 19Ab, Bb and Cb). However, the GFP signals decreased over time, consistent with 
the transient transfection. The desired GFP+ and Axl- cells are not apparent in Figure 19Ad, 
Bd and Cd, indicating that the Axl gene was not affected. 
A: 24 hours                                B: 48 hours                              C: 72 hours 
   
Figure 19: Axl and GFP expression by flow cytometry after CRISPR transfection. In each of 
A, B and C, there are four areas: a, GFP-/Axl+; b, GFP+/Axl+; c, GFP-/Axl-; d,GFP+/Axl-. 
Besides, A shows 24hours post transfection; B shows 48 hours post transfection; C shows 
72hours post transfection. 
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Discussion 
5.1 Culturing cells at atmospheric oxygen levels impacts cell 
function. 
Common practice for in vitro culture of cells is in incubators where the O2 tension 
corresponds to atmospheric levels (21% O2) [112]. However, the endogenous physiological 
O2 tension found in tissues was in the range of 2–5% [113, 114], this discrepancy may lead to 
misinterpretation of results and it may also be the reason of why effects observed in vitro 
cannot always be reproduced in vivo and vice versa [112]. According to the previous study 
results, cell culture O2 tension was reported significantly impacted on cell proliferation [116], 
metabolism [117], gene expression [118], inflammation [112], as well as differentiation [119].  
According to the data from our cell functions analysis by xCelligence system, we conclude 
that NZM cells cultured at different oxygen tensions show differences in proliferation and 
invasiveness; as for migration, the oxygen concentration did not have obvious influence. 
Yamamoto et al. proved that cells under physiological O2 tension showed a reduction in the 
proliferation rate in erythroleukemia cells [120]; Holzwarth et al. also reported that low 
physiologic oxygen tensions reduce proliferation and differentiation of human multipotent 
mesenchymal stromal cells [121]. Our data show that cells cultured in atmospheric oxygen 
level (21% O2) incubator showed higher proliferation ability than in physiological oxygen 
level (5% O2) incubator (Figure 12). Furthermore, the invasion ability analysis at both 
atmospheric and physiological oxygen levels showed important differences.  In this study, we 
showed Akt3 might play inhibitory role in melanoma cell invasion analysis (Figure 14), 
based on the data of NZM40 and NZM86 at physiological oxygen tension (5% O2). However, 
at atmospheric oxygen tension the inhibitory role cannot be observed. Besides, similar with 
proliferation, the invasion ability of the six NZM cell lines was dramatically improved at 
atmospheric oxygen tension compared with physiological oxygen tension. 
To our surprise, in migration assay we failed to show any obvious difference between 
atmospheric and physiological oxygen levels among the six NZM cell lines. However this 
needs to be further confirmed. Collectively the data suggested that oxygen concentration 
should be considered when designing and performing experiments with NZM cells. 
5.2 An important role for Axl in melanoma 
Emerging evidence suggests that Axl enhances melanoma development by different 
mechanisms. For instance, Sensi and co-workers detected high Axl expression in 22 of 58 of 
cell lines (38%) in a melanoma progression panel, and found that Axl promoted tumor cell 
migration and invasion. Axl knockdown inhibited motility, invasivity, and ability to heal a 
wound or to migrate across an endothelial barrier [77]. Pharmacological inhibition of Axl 
using the selective inhibitor BGB324/R428 also showed comparable effects in reducing 
migration and invasion [77]. 
However, although Sensi and colleagues showed that Axl depletion did not dramatically 
affect proliferation, Tworkoski et al. indicated that knockdown of Axl inhibited proliferation 
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in some lines [78]. Nevertheless, the consensus was that Axl mediated pro-invasive and 
metastatic behavior in melanoma cells [78]. In addition, Tworkoski et al. also reported 
increased Axl expression in a subset of melanoma cell lines and tumors relative to 
melanocytes and showed that targeting Axl reduced melanoma cell proliferation and 
migration, STAT3 signaling, and in vivo tumor genesis [78]. Furthermore Holland et al. 
suggested that Axl regulated endothelial tube formation, and implied that Axl may play a role 
in angiogenesis or vascular mimicry in melanoma [69]. Gjerdrum et al. revealed that EMT 
program activation led to Axl up-regulation, which was essential for invasiveness and 
spontaneous metastasis [52]. Recently, Muller et al. proved that inhibition of Axl could lead to 
melanoma cell death and strongly decrease viability in PLX4720-resistant cells. They also 
found that a low MITF/Axl ratio predicted resistance to multiple targeted cancer drugs and 
provide a rationale for clinically exploring Axl inhibitors to combat resistance in MITF-
low/Axl high, BRAF and NRAS mutant melanomas [122]. Together these studies support the 
important role of Axl in melanoma. In our study, we proved that cells with higher Axl 
expression showed higher proliferation, migration, and relatively high invasion abilities 
(Figure 12-14). Our data agreed with the results of Sensi et al. [77] and Tworkoski et al. [78]. 
All the results indicated the important role of Axl in melanoma progression and metastasis 
dissemination.  
We will further evaluate the important role of Axl in melanoma cells by cell functional 
analysis with Axl knock out cells. As our CRISPR results showed that Axl was not 
successfully knock out (Figure 18, 19), the reason leading to the failure was not clear. 
Although compared with other designer nuclease technologies such as ZFNs and TALENs, 
Cas9 represents a system that is markedly easier to design, highly specific, efficient and well-
suited for high-throughput and multiplexed gene editing for a variety of cell types and 
organisms [111]. However, in this study, we failed to knock out Axl in NZM17 cells (Figure 
18, 19). Reasons may include: Cas9 was not expressed, or there was a mutation in the 
sequence that inhibits the enzyme function; incomplete 2A sequence processing; the gRNA 
was not expressed properly; the designed gRNA was not optimal; the expression levels of 
gRNA and Cas9 were insufficient. In this study we used Cas9 nickase mutant (Cas9n) 
(Figure 5) to nick rather than cleave DNA with high specificity, in further study, we will try 
another CRISPR plasmid including Cas9 nucleases which can carry out strand-specific 
cleavage with relatively lower specificity but maybe higher efficiency.  
 
5.3 Axl contribution to drug resistance in melanoma. 
Melanomas were characterized by activating mutations in BRAF or NRAS, BRAF mutations 
occur in ~45% of melanoma patients, while NRAS mutations occur in 15–20% of melanoma 
patients [113]. These mutations activate the downstream kinases MEK and ERK within the 
MAPK pathway, leading to enhanced cellular proliferation and survival [124]. The discovery 
of the small-molecule inhibitor vemurafenib, specifically targeting the mutant BRAFV600E 
kinase, was the first standard of care for patients diagnosed with mutant BRAF metastatic 
melanoma [125–127]. Although this compound initially reduced tumour burden dramatically, 
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eventually melanomas became resistant while treatment [128]. Even patients were treated 
with a combinatorial therapy of BRAF and MEK inhibitors (dabrafenib + trametinib), 
eventually most patients also became resistant to the treatment [129, 130]. More and more 
studies found that these resistances in melanoma therapy were associated with Axl. For 
instance, Muller et al. found that cells which had lost MITF expression after prolonged 
exposure to BRAF inhibitor PLX4720, showed a strong upregulation of Axl. Besides they 
also found that increased expression and activity of Axl was seen not only in innate but also 
acquired resistance of melanoma cells [122]. In addition, Konieczkowski, D. J., et al. 
indicated that overexpression of Axl was sufficient to confer acquired resistance to RAFi and 
MEKi [124]. 
It was reported that Axl expression was detected with a significantly higher frequency in 
mutant NRAS melanomas [79]. From Kim’s results (Figure 20), in our six NZM cell lines 
(highlighted by red diagram), NZM17 and NZM40 showed mutation in NRAS. Both cell lines 
showed high proliferation, migration and invasion abilities (Figure 12-14). Because Axl was 
also showed be relevant to mutant BRAF cells, it worth further study on the role of Axl in the 
drug resistance to melanomas with BRAF or NRAS mutations. To further explore the 
resistant role of Axl in melanoma metastasis therapy, we received new NZM cell lines with 
BRAF mutation. In future we will perform more study on this direction. 
 
52 
 
Figure 20: Genetic status of the NZM cell lines. This figure showed different NZM cell lines 
were detected with different mutations including BRAF and NRAS. The six NZM cell lines 
used in our study were highlighted by red diagram. NZM17 and NZM40 showed mutation in 
NARS. Adapted from Reference [115] 
5.4 Different roles for Akt3 played in melanoma. 
In melanoma tumorigenesis, Akt signaling was proved frequently upregulated [131]. However,   
Stahl et al. proved that only Akt3, and not Akt1 or Akt2, against by small interfering RNA 
(siRNA) reduced the amount of phosphorylated (active) Akt in melanoma cells [96], and they 
also indicated that the predominant isoform Akt3 among Akt family in melanomas, was 
involved in PI3K/Akt3 pathway and played an important role in melanoma formation, 
invasion, metastasis and therapeutic resistance [96, 131]. In addition, Madhunapantula et al. 
also pointed out that activation of Akt3 was a key event regulating the development of 
melanomas, and enzymes involved in this signaling pathway regulated cell survival, 
proliferation, metastasis and are implicated in development of resistance to a variety of 
chemotherapeutic agents [132]. Furthermore, the Akt3 signaling pathway was detected 
constitutively active in ~70% of advanced-stage melanomas [133]. There was also report 
proved that overexpression of activated Akt3 enhanced growth of melanoma cells and 
knockdown of Akt3 remarkably promoted cell apoptosis [98]. It was also well-established that 
targeting Akt3 inhibited melanoma tumor development, sensitized cells to chemotherapeutic 
agents and decreased drug resistance [134]. Similarly, studies targeting Akt3 in melanomas 
using either small interfering RNA or small molecule inhibitors showed that decreased Akt3 
activity reduced tumor volume by increasing apoptosis [135, 136].   
Our data agree with that higher Akt3 expression enhanced melanoma cells grow and migrate 
(Figure 12-13), however in invasion analysis our data showed ambiguous results. On one 
hand NZM17 cell lines which had relatively higher expression of Akt3, also showed higher 
invasion ability in both atmospheric 21% O2 and physiological 5% O2; on the other hand the 
lowest Akt3 expression in gene level (NZM40, Figure 10) showed the highest invasion level, 
and the highest Akt3 expression in protein level (NZM86, Figure 11) showed the lowest 
invasion ability under physiological 5% O2 condition (Figure 14). The results of NZM 40 and 
NZM86 indicated that Akt3 might inhibit melanoma invasion. 
In previous studies, there were also some evidences suggesting that Akt3 exerted inhibitory 
effects in cancer [83]. For instance, it was reported that Akt3 had been shown to inhibit lung 
tumor growth in mice and inhibiting Akt3 can lead N-Cadherin to promote breast cancer 
metastasis [90–92]. However, in melanoma research, this is the first time Akt3 has been found 
to possibly play an inhibitory role in a melanoma cell invasion analysis.  
Similar with Axl, Akt3 was also known can mediate drug resistance. For instance, Akt3 was 
shown to cooperate with BRAF V600E in the transformation of murine melanocytes in vitro, 
and directly regulated the activity of mutant BRAF V600E [98]; it was also reported Akt3 
mediated resistance to BRAF inhibitor PLX-4720 [134]. In addition, Shao et al. proved Akt3 
promoted resistance to apoptosis when BRAF was targeted in melanomas [137]. According to 
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Kim’ data (Figure 20) and our data (Figure 10-14), later we will also further investigate the 
resistant role of Akt3 in new NZM cell lines with BRAF mutation, and further detect cell 
function variation by knocking Akt3 out with CRISPR or inhibiting Akt3 with compounds. 
5.5 The Axl-Akt3 signaling pathway may be important in 
melanoma metastasis. 
Tiron et al. in our research group had previously proposed a hypothesis model of Axl-
dependent EMT gene program maintenance via activation of nuclear Akt3 based on breast 
cancer study (Figure 3) [102]. As they found that Akt3 was upregulated by EMT and required 
for Axl-dependent regulation of mammary stem cell traits, besides they also concluded that 
EMT and stem cell functions required Axl-dependent activation of nuclear targeted Akt3 
[102]. They indicated that the Axl-Akt3 signaling pathway might be as a novel therapeutic 
target to treat advanced breast cancer. 
Our study investigated the mechanism for how Axl-Akt3 signaling affected metastasis in 
melanoma. According to our results, we showed that Axl and Akt3 expression varied in 
among the six New Zealand Melanoma cell lines (Figure 7-11) both in gene and protein level. 
The most important is that the Axl-Akt3 co-expressing NZM17 cells showed consistent 
proliferation, migration and invasion abilities both physiological oxygen tension (Figure 12-
14). As we have discussed above, Akt3 expression in invasion analysis showed two opposite 
impact: the Axl-Akt3 co-expression cell line NZM17 showed higher invasion ability in both 
atmospheric 21% O2 and physiological 5% O2; but the results of NZM40 and NZM86 
(without Axl-Akt3 co-expression) indicated that Akt3 might inhibit melanoma invasion under 
physiological 5% O2 condition (Figure 14). The reason might be Axl-Akt3 signaling pathway 
played the key role. Collectively our data suggests that Axl-Akt3 signaling pathway may be 
important in melanoma metastasis, and targets Axl-Akt3 axis may provide a novel therapy in 
melanoma metastasis. 
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Conclusion 
 
In this study, we demonstrated that Axl and Akt3 expression varied in among the New 
Zealand Melanoma cell lines, furthermore cells with higher expression of Axl showed higher 
levels of proliferation, migration and invasion; cells with higher expression of Akt3 also 
showed higher abilities of proliferation and migration, but had the lowest invasion ability 
without co-expression of Axl. Akt3 might play inhibitory role in melanoma cell invasion 
analysis at physiological oxygen tension in the absence of Axl. We found that cells kept at 
different oxygen tensions showed differences in proliferation and invasiveness but similar 
migration level, and suggested that precise oxygen concentration control should be considered 
when designing and performing experiments with NZM cells. We elucidated that the Axl-
Akt3 signaling pathway may be important in melanoma metastasis, and target the Axl-Akt3 
pathway may provide a novel therapy in melanoma metastasis. In conclusion, these results 
support new therapeutic approaches based on Axl signaling inhibition to treat metastatic 
melanoma. 
In further study, we will retry CRISPR-Cas9 system again with different plasmids again to 
permanently knock out the Axl gene in the melanoma cell lines to elucidate how Axl 
signaling contributes melanoma metastasis via Akt3. Furthermore, we will also use available 
some compounds to inhibit Axl to investigate the drug resistance among NZM cells with 
BRAF and NARS mutations. 
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